Interactive panel discussion.

Open Access

Interactive panel discussion.

Session: SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice

Topic: Chronic Heart Failure

Speaker: Professor S. Anker (Berlin, DE) Professor A. Stewart Coats (Coventry, GB) Doctor D. Tomasoni (Brescia, IT) Professor G. Rosano (London, GB)

Organised by Charité Friends & Sponsors Trust

Event: Heart Failure 2022

Congress Presentation

About the speakers

Professor Stefan Anker

Charité - University Medicine Berlin, Berlin (Germany)

158 presentations

8 followers

Professor Andrew Stewart Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)

110 presentations

21 followers

Doctor Daniela Tomasoni

Civil Hospital of Brescia, Brescia (Italy)

4 presentations

0 follower

Professor Giuseppe M C Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)

94 presentations

20 followers

5 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Anker (Berlin, DE)

Access

Slides

Video

Optimizing foundational therapies in HF ‒ can we do better?

Speaker: Professor A. Stewart Coats (Coventry, GB)

Access

Slides

Video

SGLT2 inhibition ‒ early, first-line therapy across the spectrum of HF.

Speaker: Doctor D. Tomasoni (Brescia, IT)

Access

Slides

Video

SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.

Speaker: Professor G. Rosano (London, GB)

Access

Slides

Video

Conclusion.

Speaker: Professor C. Lam (Singapore, SG)

Access

Video

Access the full session

SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice

Speakers: Professor S. Anker, Professor A. Stewart Coats, Doctor D. Tomasoni, Professor G. Rosano, Professor S. Anker...

Access

Video

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

Interactive panel discussion.

About the speakers

Professor Stefan Anker

Professor Andrew Stewart Coats

Doctor Daniela Tomasoni

Professor Giuseppe M C Rosano

5 more presentations in this session

Welcome and introduction.

Optimizing foundational therapies in HF ‒ can we do better?

SGLT2 inhibition ‒ early, first-line therapy across the spectrum of HF.

SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.

Conclusion.

Access the full session

SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice

About the event

Heart Failure 2022

ESC 365 is supported by